Search
SOLACI Congress
HomeFileStructural heart disease

Structural heart disease

View Category

Structural heart disease

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies...
Dr. Omar Tupayachi -
Learn More
Other

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an...
Dr. Omar Tupayachi -
Learn More
Structural heart disease

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the...
Dr. Omar Tupayachi -
Learn More
Structural heart disease

COMPARE TAVI: One-Year Results of a Randomized Study Comapring Two Balloon-Expandable Valves

The COMPARE TAVI organization conducted direct comparison of new transcatheter aortic valve implantation (TAVI) devices against contemporary...
Dr. Omar Tupayachi -
Learn More
Structural heart disease

Sievers Type 1 Bicuspid Valves: Which to Use?

One of the current challenges in TAVR is bicuspid aortic valves (BAV), because of their anatomical complexity,...
Dr. Carlos Fava -
Learn More
Structural Heart Disease

OPTION Trial: Left Atrial Appendage Closure

Atrial fibrillation ablation is a valid strategy. However, reoccurrence is frequent in these cases, often with asymptomatic...
Dr. Carlos Fava -
Learn More
Other

TRI-SPA Study: Tricuspid Edge-to-Edge Treatment

Tricuspid regurgitation (TR) is a condition associated with high morbidity and mortality. Currently, surgery is the recommended...
Dr. Carlos Fava -
Learn More
Structural heart disease

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher...
Dr. Omar Tupayachi -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Dr. Omar Tupayachi - 0
Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

Dr. Omar Tupayachi - 0
The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Dr. Omar Tupayachi - 0
Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

Institutional News

Watch our event on Evidence and Controversies of Renal Denervation in 2025

solaci - 0
You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

March 26 – SOLACI Webinar: Evidence and Controversies in Renal Denervation in 2025

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event supported by Medtronic. On this occasion, we will hold a 60-minute...

Uruguay Sessions 2025 | Young Interventional Cardiologists Contest

solaci - 0
Call for Case Submission LI SOLACI Regional Sessions – 16° Southern Cone  It is with great pleasure that we hereby invite all young Latin American cardiologists...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy